Type:
Educational Exhibit
Keywords:
Cancer, Chemotherapy, PET-CT, MR, CT, Peritoneum, Mesentery, Abdomen
Authors:
P. R. Kembhavi1, A. Chandramohan2, S. Kumara1, D. R. PALSETIA1, S. kumar1, A. Saklani1, A. D. Baheti1; 1Mumbai/IN, 2Vellore/IN
DOI:
10.26044/ecr2019/C-2378
Background
Peritoneal carcinomatosis is the intraperitoneal spread of tumour that does not originate from the peritoneum itself.
The finding of a peritoneal malignancy raises major therapeutic concerns and is associated with a poor prognosis.
Systemic chemotherapy regimens and palliative surgery were offered only with the aim of reducing the symptoms.
Since the 1990s ,
cytoreductive surgery (CRS) is used in the treatment of a subset of patients with peritoneal carcinomatosis.
However,
newer modalities like hyperthermic intraperitoneal chemotherapy (HIPEC) and Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC) have emerged as valuable treatment options.
Appropriate patient selection is important in optimizing the results of these treatments,
which is most commonly done using PCI.
Although determined at the time of surgical exploration or laparoscopy,
radiology also helps in predicting PCI and selecting the right patients for these newer treatments.